The global androgenetic alopecia market size was estimated to be USD 2.81 billion in 2023 and is expected to reach USD 6.90 billion by 2034 with a CAGR of 8.51% during the forecast period 2024-2034. The growing geriatric population, rising prevalence of hair loss, increasing prevalence of androgenetic alopecia, and advancements in treatment technologies will propel market expansion.
Growing rates of androgenetic alopecia, particularly in older populations, are a factor in the market's expansion. Hormonal fluctuations, lifestyle choices, and genetic predisposition are a few of the causes of the rising incidence. The most prevalent type of hair loss, androgenetic alopecia, impacts a sizable percentage of the population. The need for treatments is exacerbated by the factors that cause hair loss, such as poor food, lack of sleep, and rising stress levels. For instance, Pfizer Inc. published encouraging Phase 2 findings in July 2022 for their topical QTLY1003 (JAK inhibitor) for alopecia areata, which could additionally be useful for androgenetic alopecia.
By gender, the male segment accounted for the highest revenue-grossing segment in the global androgenetic alopecia market in 2023 owing to the higher prevalence of androgenetic alopecia in men, coupled with an increased awareness among male populations regarding available treatment options and a growing societal emphasis on aesthetic concerns, prompting a greater willingness among men to invest in hair restoration and preservation solutions. For instance, Lexington International, LLC introduced the HairMax LaserBand 82 with more extensive scalp coverage in February 2023. Additionally, the female segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness among women regarding hair care and aesthetic concerns, increasing acceptance of medical interventions for female pattern hair loss, and the continuous development of gender-specific treatment options.
By type of treatment, the medication-based treatment segment accounted for the highest revenue-grossing segment in the global androgenetic alopecia market in 2023 owing to the widespread adoption of pharmaceutical solutions, including topical and oral medications, for hair loss management. For instance, Follica, Inc. has been working on a possible cell-based therapy for androgenetic alopecia. To evaluate the product's safety and effectiveness, they started Phase 1/2a clinical research in August 2023. Additionally, the non-surgical treatments segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for minimally invasive and non-invasive solutions for Androgenetic Alopecia.
By end-user, the dermatology centers segment accounted for the highest revenue-grossing segment in the global androgenetic alopecia market in 2023 owing to the specialized expertise and comprehensive care provided by dermatologists in diagnosing and treating hair loss conditions. For instance, Sun Pharmaceutical Industries Ltd. and Aclaris signed into a strategic alliance in December 2023. In the treatment of androgenetic alopecia, Sun Pharma will have the sole right to utilize deuruxolitinib JAK inhibitors or other isotopic ruxolitinib formulations. Additionally, the home care settings segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising trend of self-care and the increasing availability of user-friendly devices and products for managing Androgenetic Alopecia at home.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, increased awareness about aesthetic procedures, and a high prevalence of Androgenetic Alopecia. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness of aesthetic procedures, a growing aging population, and rising disposable income levels. For instance, Kintor Pharmaceutical Limited reported in March 2023 that enrollment for its candidate KX-826, which treats androgenetic alopecia in men, was complete.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Growing rates of androgenetic alopecia, particularly in older populations, are a factor in the market's expansion. Hormonal fluctuations, lifestyle choices, and genetic predisposition are a few of the causes of the rising incidence. The most prevalent type of hair loss, androgenetic alopecia, impacts a sizable percentage of the population. The need for treatments is exacerbated by the factors that cause hair loss, such as poor food, lack of sleep, and rising stress levels. For instance, Pfizer Inc. published encouraging Phase 2 findings in July 2022 for their topical QTLY1003 (JAK inhibitor) for alopecia areata, which could additionally be useful for androgenetic alopecia.
By gender, the male segment accounted for the highest revenue-grossing segment in the global androgenetic alopecia market in 2023 owing to the higher prevalence of androgenetic alopecia in men, coupled with an increased awareness among male populations regarding available treatment options and a growing societal emphasis on aesthetic concerns, prompting a greater willingness among men to invest in hair restoration and preservation solutions. For instance, Lexington International, LLC introduced the HairMax LaserBand 82 with more extensive scalp coverage in February 2023. Additionally, the female segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness among women regarding hair care and aesthetic concerns, increasing acceptance of medical interventions for female pattern hair loss, and the continuous development of gender-specific treatment options.
By type of treatment, the medication-based treatment segment accounted for the highest revenue-grossing segment in the global androgenetic alopecia market in 2023 owing to the widespread adoption of pharmaceutical solutions, including topical and oral medications, for hair loss management. For instance, Follica, Inc. has been working on a possible cell-based therapy for androgenetic alopecia. To evaluate the product's safety and effectiveness, they started Phase 1/2a clinical research in August 2023. Additionally, the non-surgical treatments segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for minimally invasive and non-invasive solutions for Androgenetic Alopecia.
By end-user, the dermatology centers segment accounted for the highest revenue-grossing segment in the global androgenetic alopecia market in 2023 owing to the specialized expertise and comprehensive care provided by dermatologists in diagnosing and treating hair loss conditions. For instance, Sun Pharmaceutical Industries Ltd. and Aclaris signed into a strategic alliance in December 2023. In the treatment of androgenetic alopecia, Sun Pharma will have the sole right to utilize deuruxolitinib JAK inhibitors or other isotopic ruxolitinib formulations. Additionally, the home care settings segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising trend of self-care and the increasing availability of user-friendly devices and products for managing Androgenetic Alopecia at home.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, increased awareness about aesthetic procedures, and a high prevalence of Androgenetic Alopecia. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness of aesthetic procedures, a growing aging population, and rising disposable income levels. For instance, Kintor Pharmaceutical Limited reported in March 2023 that enrollment for its candidate KX-826, which treats androgenetic alopecia in men, was complete.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
Study Coverage
- Market Forecast by Gender, Type of Treatment, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Androgenetic Alopecia Market Report 2023 - 2034
Androgenetic Alopecia Market Analysis & Forecast by Gender 2023 - 2034 (Revenue USD Bn)
- Male
- Female
Androgenetic Alopecia Market Analysis & Forecast by Type of Treatment 2023 - 2034 (Revenue USD Bn)
- Medication-based Treatment
- Surgical Treatment
- Non-surgical Treatment
Androgenetic Alopecia Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Specialty Clinics
- Dermatology Centers
- Homecare Settings
Androgenetic Alopecia Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Androgenetic Alopecia Market: Gender Estimates & Trend Analysis
8. Androgenetic Alopecia Market: Type of Treatment Estimates & Trend Analysis
9. Androgenetic Alopecia Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Androgenetic Alopecia Market
12. Europe Androgenetic Alopecia Market
13. Asia Pacific Androgenetic Alopecia Market
14. Latin America Androgenetic Alopecia Market
15. MEA Androgenetic Alopecia Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Johnson & Johnson
- Merck & Co. Inc.
- Pfizer Inc.
- Cipla Limited
- Sun Pharmaceutical Industries Ltd.
- Histogen Inc.
- Aclaris Therapeutics Inc.
- Lexington International LLC
- Follica Inc.
- Capillus LLC
- HCell Inc.
- Concert Pharmaceuticals Inc.
- Kythera Biopharmaceuticals Inc.
- TransDerm Inc.
- Aurobindo Pharma Limited.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 2.81 Billion |
| Forecasted Market Value ( USD | $ 6.9 Billion |
| Compound Annual Growth Rate | 8.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
